Loading stock…

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (300760) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

300760Market cap $29BPrice $24.1

Country🇨🇳China

SectorHealthcare

IndustryHealthcare Equipment

Makes patient monitors, ultrasound machines, and lab diagnostics equipment used in hospitals across 190+ countries. It's China's largest medical device maker, built by three engineers who once sold electronics out of a garage in Shenzhen.

In Bastion Portfolios?

52W Return-23%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+3%4

Revenue Forecast

Rev CAGR (1y)+12%7

Rev CAGR (3y)+10%7

Rev CAGR (5y)+12%8

Earnings Forecast

EPS Growth Y+1+10%7

EPS Growth Y+2+14%7

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin28%9

Net Income Margin23%8

Free Cash Flow Margin26%9

Debt

Net Debt/EBITDA-1.610

Efficiency

ROE20%8

ROA14%9

Earnings Stability55

GEAR+VERY STRONG94

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)214

P/E Ratio (Forward 3y)183

P/BV4.83

EV Multiples

EV/EBITDA Fwd154

EV/EBIT Fwd185

Yield

Free Cash Flow Yield4.6%6

Dividend Yieldna–

Momentum

Short term

1 month return-4%6

3 month return+18%9

YTD return-14%3

Mid term

Price vs 52wHigh66%3

1 year return-33%2

Long term

3 year return-35%1

5 year return-53%1

Risk Shield

Price Risk

Beta0.48

Volatility27%8

Free Cash Flow

Free Cash Flow Margin26%9

Free Cash Flow Yield4.6%6

Quality

ROCE20%9

Earnings Stability55

Net Debt/EBITDA-1.610

02Growth

Is it actually growing, and how fast?

300760Shenzhen Mindray Bio-Medical Electronics Co.

Revenue FY25$4.8B

GROWTH RATING↗

AVERAGE67 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y+12%7

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+10%7

EPS growth, FY27E+14%7

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

It out-grows 67% of companies worldwide.

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 3%/yr over the last 3 years and is set to grow 10%/yr from here.

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 10%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

300760Shenzhen Mindray Bio-Medical Electronics Co.

Total return Current71.6%

Price return Current51.5%

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return+18%9

YTD return-14%3

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return-33%2

3-year return-35%1

5-year return-53%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+18%).

WATCH

Returns sit at the market level over the past month (-4%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-35% over three years and -53% over five), behind 90% of the market.

It's down 33% over the past year, now 34% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-14%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Mindray. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

300760Shenzhen Mindray Bio-Medical Electronics Co.

Revenue FY25$4.8B

GROWTH RATING↗

AVERAGE67 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y+12%7

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+10%7

EPS growth, FY27E+14%7

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

It out-grows 67% of companies worldwide.

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 3%/yr over the last 3 years and is set to grow 10%/yr from here.

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 10%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

300760Shenzhen Mindray Bio-Medical Electronics Co.

Total return Current71.6%

Price return Current51.5%

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return+18%9

YTD return-14%3

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return-33%2

3-year return-35%1

5-year return-53%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+18%).

WATCH

Returns sit at the market level over the past month (-4%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-35% over three years and -53% over five), behind 90% of the market.

It's down 33% over the past year, now 34% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-14%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Mindray. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community